Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of inebilizumab in adults with primary membranous nephropathy
CTR20263989Phase 3Active
- Sponsor
- Amgen
- Start
- Oct 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of inebilizumab in idiopathic membranous glomerulonephritis (IMG), sponsored by Amgen. Started Oct 2026; status: active.
02
Drugs
inebilizumab
03
Conditions
idiopathic membranous glomerulonephritis (IMG)
Beyond the preview
Go deeper on CTR20263989.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20263989.